Cutaneous plasmablastic plasmacytoma: A case report with literature review
Keywords:
Cutaneous Plasmacytoma , Case Report, Multiple Myeloma, Plasmablastic morphologyAbstract
Multiple myeloma (MM) is a hematologic malignancy often involving bone marrow and osteolytic lesions. Cutaneous involvement in MM is rare and typically signifies advanced disease. Here, we present a rare case of MM with cutaneous involvement and provide an updated review of the literature on this unusual dermatologic presentation as latest comprehensive review on cutaneous plasmacytoma dates back to 2003. A 50-year-old male with sacral plasmacytoma and elevated immunoglobulin G (IgG) was diagnosed with IgG Kappa MM, ISS stage II. After receiving radiation, chemotherapy, and stem cell transplantation, he achieved a very good partial response and began maintenance therapy with bortezomib-dexamethasone. Three years post-diagnosis, he developed biopsy-confirmed cutaneous plasmacytomas. A retrospective review of case series and reports from 2003 to 2024 using PubMed database identified 11 publications encompassing 27 patients. Our review found that IgG was the most common immunoglobulin subtype in cutaneous plasmacytoma (11/27), primarily affecting older males (15/27) (median age 73). Clinically, nodular lesions (17/27) were the most frequent presentation, predominantly located on the chest area (7/27). Histologically, plasmacytic cellular morphology (12/27) and plasmablastic morphology (11/27) were nearly equally prevalent. Prognosis varied from days to four years post-diagnosis. Despite numerous case reports, significant gaps remain in our understanding of cutaneous plasmacytoma, its risk factors, and clinical associations. Further research should prioritize prospective studies with larger, more diverse cohorts to enhance comprehension of the disease, improve diagnostic accuracy, refine treatment approaches, and ultimately improve patient outcomes.
References
1. Rajkumar SV, Kumar S. Multiple myeloma: diagnosis and treatment. Mayo Clin Proc. 2016;91(1):101-19. doi: 10.1016/j.mayocp.2015.11.007
2. Gagelmann N, Eikema DJ, Iacobelli S, et al. Impact of extramedullary disease in patients with newly diagnosed multiple myeloma undergoing autologous stem cell transplantation: a study from the Chronic Malignancies Working Party of the EBMT. Haematologica. 2018;103(5):890-7. doi: 10.3324/haematol.2017.178434
3. Usmani SZ, Heuck C, Mitchell A, et al. Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents. Haematologica. 2012;97(11):1761-7. doi: 10.3324/haematol.2012.065698
4. Abdrabou AK, Sharif FA, Fakih RE, et al. Outcomes of autologous stem cell transplantation for multiple myeloma in Saudi Arabia. Ann Saudi Med. 2021;41(4):198-205. doi: 10.5144/0256-4947.2021.198
5. Rajkumar SV. Multiple myeloma: 2022 update on diagnosis, risk stratification, and management. Am J Hematol. 2022;97(8):1086-107. doi: 10.1002/ajh.26590
6. Woo YR, Kim JS, Lim JH, et al. Prevalence and clinicopathologic characteristics of multiple myeloma with cutaneous involvement: a case series from Korea. J Am Acad Dermatol. 2018;78(3):471-8.e4. doi: 10.1016/j.jaad.2017.08.054
7. Rosenblum MD, Bredeson CN, Chang CC, Rizzo JD. Subcutaneous plasmacytomas with tropism to sites of previous trauma in a multiple myeloma patient treated with an autologous bone marrow transplant. Am J Hematol. 2003;72(4):274-7. doi: 10.1002/ajh.10296
8. Requena L, Kutzner H, Palmedo G, et al. Cutaneous involvement in multiple myeloma: a clinicopathologic, immunohistochemical, and cytogenetic study of 8 cases. Arch Dermatol. 2003;139(4):475-86. doi: 10.1001/archderm.139.4.475
9. Pereira MA, Baudrier T, Costa A, Magalhães J, Azevedo F. Cutaneous metastatic plasmacytomas with tropism for a previously injured limb. Dermatol Online J. 2008;14(9). doi: 10.5070/D337n527v0
10. Santos G, Sousa L, Fernandes T, João A. Case for diagnosis. An Bras Dermatol. 2014;89(1):173-4. doi: 10.1590/abd1806-4841.20142431
11. Gómez-Armayones S, Climent F, Servitje O. Cutaneous nodules in multiple myeloma. Actas Dermosifiliogr. 2015;106(7):581-2. doi: 10.1016/j.adengl.2015.06.009
12. Yoo J, Jo M, Kim MS, Jue MS, Park HJ, Choi KH. Cutaneous plasmacytoma: metastasis of multiple myeloma at the fracture site. Ann Dermatol. 2017;29(4):483-6. doi: 10.5021/ad.2017.29.4.483
13. Mohamed M, Alhillan A, Gupta V, et al. Relapsing cutaneous multiple myeloma responding to immunochemotherapy: a rare case report. J Med Cases. 2019;10(10):305-8. doi: 10.14740/jmc.v10i10.3382
14. Chung A, Liedtke M. Cutaneous plasmablastic plasmacytoma. Blood. 2019;134(23):2116. doi: 10.1182/blood.2019002821
15. Asavisanu K, Kasparis C, Hock YL. Cutaneous plasmacytoma: a case report. J Skin Stem Cell. 2019;6(2). doi: 10.5812/jssc.100545
16. Panse G, Subtil A, McNiff JM, et al. Cutaneous involvement in plasma cell myeloma. Am J Clin Pathol. 2021;155(1):106-16. doi: 10.1093/ajcp/aqaa122
17. Choong DJ, Ng JL, Delaney TA. Cutaneous involvement by multiple myeloma presenting as erythematous indurated plaques at the site of cardiac pacemaker insertion. JAAD Case Rep. 2021;12:54-7. doi: 10.1016/j.jdcr.2021.04.013
18. Torne R, Su WP, Winkelmann RK, Smolle J, Kerl H. Clinicopathologic study of cutaneous plasmacytoma. Int J Dermatol. 1990;29(8):562-6. doi: 10.1111/j.1365-4362.1990.tb03469.x
19. Zanelli M, Palicelli A, Sanguedolce F, et al. Cutaneous involvement in diseases with plasma cell differentiation: diagnostic approach. Curr Oncol. 2022;29(5):3026-43. doi: 10.3390/curroncol29050246
20. Caers J, Paiva B, Zamagni E, et al. Diagnosis, treatment, and response assessment in solitary plasmacytoma: updated recommendations from a European Expert Panel. J Hematol Oncol. 2018;11(1):10. doi: 10.1186/s13045-017-0549-1
21. Kilciksiz S, Karakoyun-Celik O, Agaoglu FY, Haydaroglu A. A review for solitary plasmacytoma of bone and extramedullary plasmacytoma. ScientificWorldJ. 2012;2012:895765. doi: 10.1100/2012/895765
22. Jurczyszyn A, Olszewska-Szopa M, Hungria V, et al. Cutaneous involvement in multiple myeloma: a multi-institutional retrospective study of 53 patients. Leuk Lymphoma. 2016;57(9):2071-6. doi: 10.3109/10428194.2015.1128542
23. Alberts DS, Lynch P. Cutaneous plasmacytomas in myeloma: relationship to tumor cell burden. Arch Dermatol. 1978;114(12):1784-7. doi: 10.1001/archderm.1978.01640240026007
24. Kois JM, Sexton FM, Lookingbill DP. Cutaneous manifestations of multiple myeloma. Arch Dermatol. 1991;127(1):69-74. doi: 10.1001/archderm.1991.01680010079012
25. Hobbs JR, Corbett AA. Younger age of presentation and extraosseous tumour in IgD myelomatosis. Br Med J. 1969;1(5641):412-4.
26. Morè S, Corvatta L, Manieri VM, Morsia E, Poloni A, Offidani M. Novel immunotherapies and combinations: the future landscape of multiple myeloma treatment. Pharmaceuticals (Basel). 2023;16(11):1628. doi: 10.3390/ph16111628
27. Miller K, Hashmi H, Rajeeve S. Beyond BCMA: the next wave of CAR T cell therapy in multiple myeloma. Front Oncol. 2024;14:1398902. doi: 10.3389/fonc.2024.1398902
28. Arnall JR, Maples KT, Harvey RD, Moore DC. Daratumumab for the treatment of multiple myeloma: a review of clinical applicability and operational considerations. Ann Pharmacother. 2022;56(8):927-40.
29. Martino EA, Bruzzese A, Iaccino E, et al. Isatuximab in multiple myeloma. Expert Opin Biol Ther. 2023;23(4):315-8. doi: 10.1080/14712598.2023.219328
30. Syed YY. Selinexor-bortezomib-dexamethasone: a review in previously treated multiple myeloma. Target Oncol. 2023;18(2):303-10. doi: 10.1007/s11523-022-00945-3
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Khalid M. AlHusain , Haya A. AlHemli, Meshal A. Bukhari , Nadya A. Al-Faraidy , Lenah Y. Shaikh, Reem AlRabeh , Ayed AlGarni

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Transfer of Copyright and Permission to Reproduce Parts of Published Papers.
Authors retain the copyright for their published work. No formal permission will be required to reproduce parts (tables or illustrations) of published papers, provided the source is quoted appropriately and reproduction has no commercial intent. Reproductions with commercial intent will require written permission and payment of royalties.